Close Menu

NEW YORK ─ The US Food and Drug Administration on Friday granted Emergency Use Authorizations for the first two COVID-19 serology tests that display an estimated quantity of antibodies present in a person's blood.

The tests, the Advia Centaur SARS-CoV-2 IgG (COV2G) and Atellica IM SARS-CoV-2 IgG (COV2G) developed by Siemens Healthineers, are semi-quantitative. They do not display a precise measurement, but they estimate the quantity of a patient's antibodies produced against SARS-CoV-2 infection, the FDA said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.